Table 1.
Baseline characteristics
| Variables | n = 32 |
|---|---|
| Age, years | 82 ± 5 |
| Male, n (%) | 17 (53) |
| Body mass index, kg/m2 | 21.3 ± 3.8 |
| STS-PROM score, % | 5.1 (4.1–7.1) |
| Past history, n (%) | |
| Hypertension | 23 (72) |
| Dyslipidemia | 20 (63) |
| Diabetes mellitus | 11 (34) |
| Atrial fibrillation | 4 (13) |
| Coronary artery disease | 12 (38) |
| Stroke | 5 (16) |
| Laboratory data | |
| Hemoglobin, g/dL | 11.5 ± 1.4 |
| Creatinine, mg/dL | 0.83 (0.71–1.14) |
| NT-proBNP, pg/mL | 1322 (568–3145) |
| Echocardiography | |
| LVEDD, mm | 46.7 (43.0–50.0) |
| LVEF, % | 61 (54–70) |
| SVI, mL/m2 | 46.5 ± 12.4 |
| IVS, mm | 12.0 ± 2.0 |
| LVMI, g/m2 | 117.5 (102–141) |
| LAVI, mL/m2 | 45.5 (39.7–63.0) |
| E/A ratio | 0.70 (0.56–0.97) |
| E/e’ ratio | 13.1 ± 4.8 |
| AVAI, cm2/m2 | 0.45 ± 0.11 |
| Mean transaortic PG, mmHg | 53 ± 21 |
| Computed tomography | |
| Aortic annular area, mm2 | 444 (388–480) |
| Aortic annular perimeter, mm | 75.7 (70.7–80.5) |
| Bicuspid valve, n (%) | 2 (6) |
| Ascending aortic diameter, mm | 33.2 ± 3.7 |
| Access route for TAVR, n (%) | |
| Femoral | 28 (88) |
| Apical | 2 (6) |
| Subclavian | 2 (6) |
| TAVR model, n (%) | |
| SAPIEN 3 | 26 (81) |
| Evolut R | 3 (9) |
| Evolut PRO | 3 (9) |
| THV size, n (%) | |
| 23 mm | 11 (34) |
| 26 mm | 13 (41) |
| 29 mm | 8 (25) |
Continuous variables are presented as mean ± standard deviation if normally distributed, and median (interquartile range) if not normally distributed
Categorical variables are presented as number of patients (%)
AVAI aortic valve area index; IVS interventricular septum; LAVI left atrial volume index; LVEDD left ventricular end-diastolic dimension; LVEF left ventricular ejection fraction; LVMI left ventricular mass index; NT-proBNP N-terminal pro-brain natriuretic peptide; PG pressure gradient; STS-PROM Society of Thoracic Surgeons Predicted Risk of Mortality; SVI stroke volume index; TAVR transcatheter aortic valve replacement; TAVR transcatheter aortic valve replacement